Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Tang on the Current Role for Radiation Therapy in Advanced RCC

September 23rd 2024

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC

September 19th 2024

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

Dr Drakaki on Paradigm-Shifting Trials in Non–Clear Cell RCC

September 19th 2024

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC

September 19th 2024

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

Rare Case Study of ALK+ Advanced RCC Highlights Drive for Personalized Medicine in Kidney Cancer

September 18th 2024

Alexandra Drakaki, MD, dives into a case study of a patient with ALK-positive RCC that exemplified the importance of NGS and precision medicine in kidney cancer.

Dr Drakaki on the Evolution of Non–Clear Cell RCC Subtype Classifications

September 18th 2024

Alexandra Drakaki, MD, PhD, discusses how the classification of subtypes of non–clear cell renal cell carcinoma has evolved in recent years.

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

September 17th 2024

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

September 17th 2024

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC

September 15th 2024

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.

Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC

September 13th 2024

The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line therapy.

Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC

September 13th 2024

Belzutifan improved PFS and ORR but failed to deliver a significant improvement in OS vs everolimus in pretreated advanced clear cell renal cell carcinoma.

Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC

September 13th 2024

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care

September 13th 2024

Adam E. Singer, MD, PhD, highlights how cabozantinib and nivolumab treatment compares with other therapies in terms of efficacy and safety in RCC.

More Precise Classifications of Non–Clear Cell RCC Are Required to Improve Personalized Treatment

September 12th 2024

Alexandra Drakaki, MD, expands on the need to improve specific classifications in non–clear cell renal cell carcinoma.

Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC

September 12th 2024

Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.

Dr Braun on the Role of Biomarkers in Guiding Adjuvant Treatment for RCC

September 11th 2024

David A. Braun, MD, PhD, discusses the role of biomarkers in guiding adjuvant treatment strategies for renal cell carcinoma.

Dr Drakaki on the Investigation of Zanzalintinib in Advanced Non–Clear Cell RCC

September 10th 2024

Alexandra Drakaki, MD, PhD, discusses the potential role of zanzalintinib in advanced non–clear cell renal cell carcinoma.

Dr Lee on Treatment Considerations for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

September 5th 2024

John K. Lee, MD, PhD, discusses treatment considerations for the use of enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.

Dr Yekedüz on a Case Study of Adjuvant Treatment Options in ccRCC

September 4th 2024

Emre Yekedüz, MD, discusses a case study shared via social media that evaluated treatment options for a patient with clear cell renal cell carcinoma.

Baseline Radiologic Tumor Burden Is Prognostic for OS in Metastatic ccRCC

September 4th 2024

Rashad Nawfal, MD, discusses the association between radiologic tumor burden and OS in patients with metastatic ccRCC who had received frontline IO.